Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cloudgoose Biology is a biopharmaceutical company headquartered in Suzhou, China, dedicated to the development of targeted protein degradation (TPD) medicines. The company leverages its proprietary Glue-Base platform to systematically discover and optimize molecular glues and PROTACs for high-value, previously undruggable targets. Their pipeline primarily focuses on innovative therapies for oncology and autoimmune diseases. By integrating structural biology, computational chemistry, and high-throughput screening, Cloudgoose aims to accelerate the delivery of precision medicines. The firm is backed by prominent venture capital investors and operates out of the Suzhou BioBAY industrial cluster.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cloudgoose Biology Science & Technology.